Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aerpio Pharmaceuticals Inc (ARPO)

Aerpio Pharmaceuticals Inc (ARPO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,330
  • Shares Outstanding, K 47,112
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,270 K
  • 60-Month Beta 2.14
  • Price/Sales 4.92
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade ARPO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 +45.53%
on 11/06/20
1.9200 -6.77%
on 11/17/20
+0.4800 (+36.64%)
since 11/04/20
3-Month
1.1325 +58.06%
on 09/14/20
1.9200 -6.77%
on 11/17/20
+0.5700 (+46.72%)
since 09/04/20
52-Week
0.4200 +326.19%
on 03/19/20
1.9200 -6.77%
on 11/17/20
+1.1901 (+198.38%)
since 12/04/19

Most Recent Stories

More News
Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study

Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

ALNY : 129.56 (-1.23%)
ALIM : 4.33 (-1.59%)
APTO : 6.12 (-3.01%)
ARPO : 1.7900 (+2.29%)
Five Star (FVE) in Focus: Stock Moves 5.8% Higher

Five Star (FVE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

FVE : 7.15 (+6.08%)
ARPO : 1.7900 (+2.29%)
Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day

Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day

DE : 253.39 (+0.28%)
CHS : 1.6300 (-1.21%)
RGEN : 188.33 (+0.60%)
TCON : 8.89 (-2.84%)
ARPO : 1.7900 (+2.29%)
BioNTech (BNTX) Surges: Stock Moves 6.2% Higher

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ARPO : 1.7900 (+2.29%)
BNTX : 120.00 (+1.11%)
3 Biotech Stocks to Buy on First Vaccine Approval Optimism

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical...

PFE : 40.34 (+0.62%)
RGEN : 188.33 (+0.60%)
TCON : 8.89 (-2.84%)
ARPO : 1.7900 (+2.29%)
Strength Seen in Aptose (APTO): Stock Soars 5.3%

Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

APTO : 6.12 (-3.01%)
ARPO : 1.7900 (+2.29%)
Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19

Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other...

ARPO : 1.7900 (+2.29%)
GOSS : 9.26 (+3.35%)
Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10

Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other...

ARPO : 1.7900 (+2.29%)
GOSS : 9.26 (+3.35%)
Aravive Appoints Michael W. Rogers to Board of Directors

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that Michael W. Rogers joined the Company's Board of Directors. Mr. Rogers...

ARAV : 5.74 (+1.06%)
ARPO : 1.7900 (+2.29%)
ACOR : 0.7976 (+1.08%)
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial

Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other...

ARPO : 1.7900 (+2.29%)
GOSS : 9.26 (+3.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB'9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals...

See More

Key Turning Points

2nd Resistance Point 1.8433
1st Resistance Point 1.8167
Last Price 1.7900
1st Support Level 1.7467
2nd Support Level 1.7033

See More

52-Week High 1.9200
Last Price 1.7900
Fibonacci 61.8% 1.3470
Fibonacci 50% 1.1700
Fibonacci 38.2% 0.9930
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar